What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
The evidence suggests that esketamine is likely more effective than placebo plus oral antidepressants for patients who have not responded to at least three treatments. However, the trials were short, and the long-term benefits remain uncertain. The committee noted that the clinical evidence is limited and does not fully represent the Healthcare population, particularly excluding those with severe characteristics such as psychosis or recent suicidal ideation.
Does the economic case hold at the expected price? — Cost effectiveness
The cost-effectiveness estimates for esketamine are highly uncertain due to the reliance on clinical evidence that does not reflect expected Healthcare use. The committee noted that the ICERs presented were likely underestimates, and significant uncertainties in the economic model raise concerns about the overall value of esketamine.
Is there quality-of-life evidence payers weigh? — Quality of life
While there are indications of some improvement in HRQoL, the evidence is primarily derived from short-term studies and lacks robust long-term data. The committee expressed concerns about the generalizability of the HRQoL data to the broader Healthcare population, particularly given the exclusion of certain patient groups in the trials.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Esketamine has a generally acceptable safety profile, with manageable adverse effects. However, the need for close monitoring and the potential for serious adverse events, such as dissociative states, require careful consideration in clinical practice. The committee acknowledged the importance of monitoring to mitigate risks.
Was the drug compared against what payers expect? — Comparator Selection
The trials primarily compared esketamine with placebo plus oral antidepressants, which may not accurately reflect clinical practice where esketamine is likely used later in the treatment pathway. The committee noted that more relevant comparators, such as augmentation therapies, were not adequately addressed in the evidence.
Is the population defined the way payers need it? — Patient Population and Subgroups
The evidence includes a narrow patient population that does not fully represent the broader group of individuals with treatment-resistant depression. The committee highlighted concerns about the generalizability of the trial results to the Healthcare population, particularly regarding the exclusion of patients with severe comorbidities.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Integrating esketamine into existing care pathways may require significant adjustments, including infrastructure changes and additional training for healthcare providers. The committee noted that the proposed implementation plan may not be feasible without substantial investment.
Are the wider system costs understood? — Resource Use and Cost Implications
The economic model’s assumptions about resource use and costs are highly uncertain, particularly regarding the healthcare resource use in treatment-resistant depression. The committee expressed concerns about the potential underestimation of costs associated with implementing esketamine in clinical practice.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
While the evidence base includes phase 3 trials, there are significant limitations regarding the generalizability and applicability of the results to the Healthcare population. The committee noted that the evidence is not robust enough to support a confident recommendation for esketamine.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
There are substantial uncertainties regarding the long-term effectiveness and cost-effectiveness of esketamine, which could impact its use in clinical practice. The committee highlighted the need for further research to address these uncertainties and improve the evidence base.
